TN2015000135A1 - Modified release formulations for oprozomib - Google Patents

Modified release formulations for oprozomib

Info

Publication number: TN2015000135A1
Authority: TN; Tunisia
Prior art keywords: oprozomib; modified release; release formulations; release pharmaceutical; formulations
Prior art date: 2012-10-24

Application number

TNP2015000135A

Other languages

English (en)

Inventor

Mouhannad Jumaa

Tony Muchamuel

Naveen Bejugam

Christopher J Kirk

Rahul Vishram Manek

Sanjeev Sharma

Hansen Wong

Original Assignee

Onyx Therapeutics Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-10-24

Filing date

2015-04-08

Publication date

2016-10-03

2015-04-08 Application filed by Onyx Therapeutics Inc filed Critical Onyx Therapeutics Inc

2016-10-03 Publication of TN2015000135A1 publication Critical patent/TN2015000135A1/fr

Links

108010064641 ONX 0912 Proteins 0.000 title abstract 2
238000009472 formulation Methods 0.000 title abstract 2
239000000203 mixture Substances 0.000 title abstract 2
SWZXEVABPLUDIO-WSZYKNRRSA-N n-[(2s)-3-methoxy-1-[[(2s)-3-methoxy-1-[[(2s)-1-[(2r)-2-methyloxiran-2-yl]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]-2-methyl-1,3-thiazole-5-carboxamide Chemical compound N([C@@H](COC)C(=O)N[C@@H](COC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)[C@]1(C)OC1)C(=O)C1=CN=C(C)S1 SWZXEVABPLUDIO-WSZYKNRRSA-N 0.000 title abstract 2
229950005750 oprozomib Drugs 0.000 title abstract 2
239000008194 pharmaceutical composition Substances 0.000 abstract 2
-1 e.g. Substances 0.000 abstract 1
238000013265 extended release Methods 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
239000007909 solid dosage form Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Immunology (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Oncology (AREA)
Biomedical Technology (AREA)
Hospice & Palliative Care (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Hematology (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Pulmonology (AREA)
Otolaryngology (AREA)
Physical Education & Sports Medicine (AREA)
Psychiatry (AREA)
Tropical Medicine & Parasitology (AREA)
Diabetes (AREA)
Communicable Diseases (AREA)
Virology (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

TNP2015000135A 2012-10-24 2015-04-08 Modified release formulations for oprozomib TN2015000135A1 (en)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US201261717975P	2012-10-24	2012-10-24
US201261721244P	2012-11-01	2012-11-01
US201361793087P	2013-03-15	2013-03-15
PCT/US2013/066679 WO2014066681A1 (fr)	2012-10-24	2013-10-24	Formulations à libération modifiée pour l'oprozomib

Publications (1)

Publication Number	Publication Date
TN2015000135A1 true TN2015000135A1 (en)	2016-10-03

Family

ID=50485877

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TNP2015000135A TN2015000135A1 (en)	2012-10-24	2015-04-08	Modified release formulations for oprozomib

Country Status (24)

Country	Link
US (2)	US9295708B2 (fr)
EP (1)	EP2912025A4 (fr)
JP (1)	JP6505604B2 (fr)
KR (1)	KR20150070406A (fr)
CN (1)	CN104968650A (fr)
AP (1)	AP3681A (fr)
AR (1)	AR093126A1 (fr)
AU (1)	AU2013334258A1 (fr)
BR (1)	BR112015008572A2 (fr)
CA (1)	CA2888039A1 (fr)
CL (1)	CL2015001085A1 (fr)
CR (1)	CR20150266A (fr)
EA (1)	EA201590797A1 (fr)
HK (2)	HK1208222A1 (fr)
IL (1)	IL238244A0 (fr)
IN (1)	IN2015DN03921A (fr)
MX (1)	MX2015005069A (fr)
PE (1)	PE20151051A1 (fr)
PH (1)	PH12015500823A1 (fr)
SG (1)	SG11201502849XA (fr)
TN (1)	TN2015000135A1 (fr)
TW (1)	TW201422255A (fr)
UY (1)	UY35091A (fr)
WO (1)	WO2014066681A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TWI568722B (zh)	2012-06-15	2017-02-01	葛蘭馬克製藥公司	作爲ｍＰＧＥＳ－１抑制劑之三唑酮化合物
HK1252549A1 (zh)	2015-06-19	2019-05-31	Biotie Therapies, Inc.	控释tozadenant制剂
CN105949279A (zh) *	2016-04-27	2016-09-21	浙江大学	蛋白酶体抑制剂Oprozomib及其类似物的制备方法
WO2018005781A1 (fr) *	2016-06-29	2018-01-04	Kezar Life Sciences	Procédé de préparation d'inhibiteur d'immunoprotéasome de peptide époxycétone et précurseurs associés
WO2018057453A1 (fr)	2016-09-21	2018-03-29	Amgen Inc.	Formules à libération immédiate pour oprozomib
WO2018112078A1 (fr)	2016-12-14	2018-06-21	Amgen Inc.	Formes pharmaceutiques à libération modifiée et à rétention gastrique pour oprozomib et leur procédé de fabrication
US11401334B2 (en)	2017-09-14	2022-08-02	Glaxosmithkline Intellectual Property Development Limited	Combination treatment for cancer with anti-BCMA binding protein and proteosome inhibitor
CN110357940A (zh) *	2019-08-02	2019-10-22	苏州艾和医药科技有限公司	奥普佐米合成工艺研究
JP2025516629A (ja)	2022-05-11	2025-05-30	セルジーンコーポレーション	Ｔ細胞療法に関連する方法および使用、ならびにその生成

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5126145A (en) *	1989-04-13	1992-06-30	Upsher Smith Laboratories Inc	Controlled release tablet containing water soluble medicament
JPH06199657A (ja) *	1992-12-10	1994-07-19	Sumitomo Pharmaceut Co Ltd	徐放性製剤
AU4499697A (en)	1996-09-13	1998-04-02	New York University	Method for treating parasitic diseases with proteasome inhibitors
JP4748839B2 (ja) *	1999-03-25	2011-08-17	大塚製薬株式会社	シロスタゾール製剤
BR0207157A (pt) *	2001-02-12	2004-02-17	Wyeth Corp	Sal de succinato de o-desmetil-venlafaxina
US8119154B2 (en) *	2004-04-30	2012-02-21	Allergan, Inc.	Sustained release intraocular implants and related methods
LT2623113T (lt) *	2005-11-09	2017-07-10	Onyx Therapeutics, Inc.	Junginiai, skirti fermentų slopinimui
US20100172988A1 (en) *	2006-01-10	2010-07-08	Kissei Pharmaceutical Co., Ltd.	Sustained release preparation and method for production thereof
WO2008140782A2 (fr)	2007-05-10	2008-11-20	Proteolix, Inc.	Composés d'inhibition enzymatique
ES2684340T3 (es) *	2007-10-04	2018-10-02	Onyx Therapeutics, Inc.	Inhibidores de proteasa epoxi cetona de péptidos cristalinos y síntesis de cetoepóxidos de aminoácidos
TWI504598B (zh) *	2009-03-20	2015-10-21	Onyx Therapeutics Inc	結晶性三肽環氧酮蛋白酶抑制劑

2013
- 2013-10-22 TW TW102138163A patent/TW201422255A/zh unknown
- 2013-10-22 UY UY0001035091A patent/UY35091A/es not_active Application Discontinuation
- 2013-10-24 CN CN201380067772.0A patent/CN104968650A/zh active Pending
- 2013-10-24 US US14/062,759 patent/US9295708B2/en not_active Expired - Fee Related
- 2013-10-24 AU AU2013334258A patent/AU2013334258A1/en not_active Abandoned
- 2013-10-24 MX MX2015005069A patent/MX2015005069A/es unknown
- 2013-10-24 IN IN3921DEN2015 patent/IN2015DN03921A/en unknown
- 2013-10-24 HK HK15108858.7A patent/HK1208222A1/xx unknown
- 2013-10-24 EA EA201590797A patent/EA201590797A1/ru unknown
- 2013-10-24 CA CA2888039A patent/CA2888039A1/fr not_active Abandoned
- 2013-10-24 BR BR112015008572A patent/BR112015008572A2/pt not_active Application Discontinuation
- 2013-10-24 HK HK16103699.0A patent/HK1215709A1/zh unknown
- 2013-10-24 AR ARP130103868A patent/AR093126A1/es unknown
- 2013-10-24 EP EP13849834.0A patent/EP2912025A4/fr not_active Withdrawn
- 2013-10-24 WO PCT/US2013/066679 patent/WO2014066681A1/fr not_active Ceased
- 2013-10-24 KR KR1020157013739A patent/KR20150070406A/ko not_active Withdrawn
- 2013-10-24 SG SG11201502849XA patent/SG11201502849XA/en unknown
- 2013-10-24 PE PE2015000537A patent/PE20151051A1/es not_active Application Discontinuation
- 2013-10-24 JP JP2015539810A patent/JP6505604B2/ja not_active Expired - Fee Related
- 2013-10-24 AP AP2015008387A patent/AP3681A/xx active
2015
- 2015-04-08 TN TNP2015000135A patent/TN2015000135A1/fr unknown
- 2015-04-12 IL IL238244A patent/IL238244A0/en unknown
- 2015-04-15 PH PH12015500823A patent/PH12015500823A1/en unknown
- 2015-04-24 CL CL2015001085A patent/CL2015001085A1/es unknown
- 2015-05-20 CR CR20150266A patent/CR20150266A/es unknown
2016
- 2016-01-28 US US15/008,634 patent/US20160213610A1/en not_active Abandoned

Also Published As

Publication number	Publication date
MX2015005069A (es)	2015-07-17
IN2015DN03921A (fr)	2015-10-02
JP6505604B2 (ja)	2019-04-24
PH12015500823A1 (en)	2015-06-22
KR20150070406A (ko)	2015-06-24
HK1215709A1 (zh)	2016-09-09
BR112015008572A2 (pt)	2017-07-04
AR093126A1 (es)	2015-05-20
CR20150266A (es)	2015-08-14
TW201422255A (zh)	2014-06-16
IL238244A0 (en)	2015-06-30
EP2912025A4 (fr)	2016-06-08
JP2015535255A (ja)	2015-12-10
AP3681A (en)	2016-04-19
CL2015001085A1 (es)	2015-08-28
UY35091A (es)	2014-05-30
EA201590797A1 (ru)	2016-02-29
AP2015008387A0 (en)	2015-04-30
HK1208222A1 (en)	2016-02-26
CN104968650A (zh)	2015-10-07
US20140113855A1 (en)	2014-04-24
WO2014066681A1 (fr)	2014-05-01
SG11201502849XA (en)	2015-05-28
CA2888039A1 (fr)	2014-05-01
AU2013334258A1 (en)	2015-04-30
US9295708B2 (en)	2016-03-29
US20160213610A1 (en)	2016-07-28
EP2912025A1 (fr)	2015-09-02
PE20151051A1 (es)	2015-08-03

Publication	Publication Date	Title
TN2015000135A1 (en)	2016-10-03	Modified release formulations for oprozomib
SG10201810985XA (en)	2019-01-30	Tofacitinib oral sustained release dosage forms
EA201200937A1 (ru)	2013-02-28	Твердая лекарственная форма тикагрелора
IN2012DN06720A (fr)	2015-10-23
MX348823B (es)	2017-06-30	Formulaciones estables de linaclotida.
MX354210B (es)	2018-02-16	Formas farmaceuticas orales de liberacion controlada de farmacos escasamente solubles y los usos de estas.
MY165149A (en)	2018-02-28	Use of binders for manufacturing storage stable formulations
PH12012502083A1 (en)	2017-07-26	Manufacturing of active-free granules and tablets comprising the same
PH12012502082A1 (en)	2022-10-05	Combination of active loaded granules with additional actives
MY157673A (en)	2016-07-15	Pharmaceutical compositions comprising hydromorphone and naloxone
TN2011000651A1 (en)	2013-05-24	Solid pharmaceutical fixed dose compositions comprising irbesartan and amlodipine their preparation and their therapeutic application
PH12014501408A1 (en)	2014-09-22	Immediate release multi unit pellet system
MX2016006087A (es)	2016-08-12	Formulaciones de desintegracion rapida y metodos de uso.
UA105285C2 (uk)	2014-04-25	Тверда фармацевтична композиція раміприлу і безилату амлодипіну і її отримання
TN2016000557A1 (en)	2018-04-04	Pharmaceutical dosage forms
MX2015006217A (es)	2015-11-16	Tableta dispersable.
ZA201500411B (en)	2016-01-27	Formulations for the preparation of immediate-release tablets for oral administration containing low-dose mifepristone, tablets thus obtained and their preparation process
MY159675A (en)	2017-01-13	Clerodane derivatives for modulation of leukotriene receptor activity and related diseases
EA201491477A1 (ru)	2015-02-27	Фармацевтические составы, содержащие флупиртин
WO2013168179A3 (fr)	2014-01-30	Formulations pharmaceutiques à libération contrôlée d'agents antiviraux
IN2015MU00907A (fr)	2015-04-24
ES2422657A1 (es)	2013-09-12	Composición farmacéutica sólida de cilostazol
WO2014064711A3 (fr)	2014-06-19	Procédés d'administration de raltégravir et de compositions de raltégravir
WO2011107922A3 (fr)	2012-04-26	Composition de milnacipran à libération prolongée
IN2013MU01330A (fr)	2015-04-10